Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $23.84 and last traded at $24.30, with a volume of 852658 shares. The stock had previously closed at $24.00.

Analyst Upgrades and Downgrades

COLL has been the topic of several research reports. Barclays decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 19th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Finally, Piper Sandler restated a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Collegium Pharmaceutical Stock Performance

The company has a 50-day simple moving average of $32.34 and a two-hundred day simple moving average of $34.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. The firm has a market capitalization of $791.21 million, a P/E ratio of 19.60 and a beta of 0.72.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same quarter in the prior year, the business earned $1.68 EPS. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Group One Trading LLC bought a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 427 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at $61,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after acquiring an additional 2,190 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.